Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
Eton Pharmaceuticals (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, announced its leadership team's participation in two upcoming investor conferences. CEO Sean Brynjelsen, CFO James Gruber, and CBO David Krempa will attend:
1. The 25th Annual B. Riley Securities Investor Conference on May 22, 2025, at 11:15am ET in Marina Del Rey, California, featuring a fireside chat
2. The 22nd Annual Craig-Hallum Institutional Investor Conference on May 28, 2025, in Minneapolis, Minnesota
One-on-one meetings can be arranged through B. Riley or Craig Hallum representatives. No webcasts will be available for either conference.
Eton Pharmaceuticals (Nasdaq: ETON), un'azienda farmaceutica specializzata in trattamenti per malattie rare, ha annunciato la partecipazione del suo team dirigenziale a due prossimi eventi per investitori. Il CEO Sean Brynjelsen, il CFO James Gruber e il CBO David Krempa saranno presenti a:
1. La 25ª Conferenza Annuale per Investitori di B. Riley Securities il 22 maggio 2025, alle 11:15 ET, a Marina Del Rey, California, con una chiacchierata informale
2. La 22ª Conferenza Annuale per Investitori Istituzionali di Craig-Hallum il 28 maggio 2025, a Minneapolis, Minnesota
È possibile organizzare incontri individuali tramite i rappresentanti di B. Riley o Craig Hallum. Non saranno disponibili webcast per nessuna delle due conferenze.
Eton Pharmaceuticals (Nasdaq: ETON), una compañía farmacéutica especializada en tratamientos para enfermedades raras, anunció la participación de su equipo directivo en dos próximas conferencias para inversores. El CEO Sean Brynjelsen, el CFO James Gruber y el CBO David Krempa asistirán a:
1. La 25ª Conferencia Anual de Inversores de B. Riley Securities el 22 de mayo de 2025 a las 11:15 am ET en Marina Del Rey, California, con una charla informal
2. La 22ª Conferencia Anual de Inversores Institucionales de Craig-Hallum el 28 de mayo de 2025 en Minneapolis, Minnesota
Se pueden organizar reuniones individuales a través de los representantes de B. Riley o Craig Hallum. No habrá transmisiones web disponibles para ninguna de las dos conferencias.
Eton Pharmaceuticals (나스닥: ETON), 희귀 질환 치료제 전문 제약회사가 다가오는 두 개의 투자자 컨퍼런스에 경영진이 참석할 예정임을 발표했습니다. CEO Sean Brynjelsen, CFO James Gruber, CBO David Krempa가 참석할 예정입니다:
1. 2025년 5월 22일 오전 11시 15분 ET, 캘리포니아 마리나 델 레이에서 열리는 제25회 연례 B. Riley Securities 투자자 컨퍼런스에서의 대담
2. 2025년 5월 28일 미네소타주 미니애폴리스에서 열리는 제22회 연례 Craig-Hallum 기관 투자자 컨퍼런스
1:1 미팅은 B. Riley 또는 Craig Hallum 담당자를 통해 조율할 수 있습니다. 두 컨퍼런스 모두 웹캐스트는 제공되지 않습니다.
Eton Pharmaceuticals (Nasdaq : ETON), une entreprise pharmaceutique spécialisée dans les traitements des maladies rares, a annoncé la participation de son équipe dirigeante à deux prochaines conférences pour investisseurs. Le CEO Sean Brynjelsen, le CFO James Gruber et le CBO David Krempa assisteront à :
1. La 25e conférence annuelle des investisseurs B. Riley Securities le 22 mai 2025 à 11h15 ET à Marina Del Rey, Californie, avec une discussion informelle
2. La 22e conférence annuelle des investisseurs institutionnels Craig-Hallum le 28 mai 2025 à Minneapolis, Minnesota
Des réunions individuelles peuvent être organisées via les représentants de B. Riley ou Craig Hallum. Aucun webcast ne sera disponible pour ces deux conférences.
Eton Pharmaceuticals (Nasdaq: ETON), ein Pharmaunternehmen, das sich auf die Behandlung seltener Krankheiten spezialisiert hat, gab die Teilnahme seines Führungsteams an zwei bevorstehenden Investorenkonferenzen bekannt. CEO Sean Brynjelsen, CFO James Gruber und CBO David Krempa werden teilnehmen an:
1. Der 25. jährlichen B. Riley Securities Investorenkonferenz am 22. Mai 2025 um 11:15 Uhr ET in Marina Del Rey, Kalifornien, mit einem Gespräch am Kamin
2. Der 22. jährlichen Craig-Hallum Institutional Investor Conference am 28. Mai 2025 in Minneapolis, Minnesota
Einzelgespräche können über Vertreter von B. Riley oder Craig Hallum arrangiert werden. Für keine der beiden Konferenzen werden Webcasts verfügbar sein.
- None.
- None.
DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, James Gruber, Chief Financial Officer, and David Krempa, Chief Business Officer, will participate in two upcoming investor conferences as follows:
- The 25th Annual B. Riley Securities Investor Conference
Date: Thursday, May 22, 2025, at 11:15am ET/8:15am PT (Fireside Chat)
Location: The Ritz-Carlton, Marina Del Rey, California
- The 22nd Annual Craig-Hallum Institutional Investor Conference
Date: Wednesday, May 28, 2025
Location: Depot Renaissance Hotel, Minneapolis, Minnesota
To schedule a 1x1 meeting with the Company, please contact your B. Riley or Craig Hallum institutional sales representative.
There is no webcast for these conferences.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.
FAQ
When is Eton Pharmaceuticals (ETON) presenting at the B. Riley Securities Investor Conference 2025?
Who will represent Eton Pharmaceuticals (ETON) at the upcoming investor conferences?
Where is the Craig-Hallum Institutional Investor Conference 2025 being held?
How can investors schedule meetings with Eton Pharmaceuticals (ETON) at these conferences?
